Recent Company News

• 04:06 AM ET Jul 22, 2025
  

  StreetAccount Sector Preview - Japan Chemicals Apr-Jun Earnings

• 02:42 AM ET Jun 24, 2025
  

  Teijin receives additional indication approval for Xeomin in Japan for treatment of chronic sialorrhea (¥1165.5000, 0)

• 10:11 PM ET Jun 02, 2025
  

  MHLW grants orphan drug designation to Teijin's navepegritide (TransCon CNP) for the treatment of chondrodysplasia (¥1136.5000, -5.5)

• 10:41 PM ET May 11, 2025
  

  Teijin reports Q4 net income attributable (¥22.60B) vs FactSet (¥25.60B) [1 est] (¥1220.0000, +15.5)

• 10:30 PM ET Apr 24, 2025
  

  StreetAccount Sector Preview - Japan Chemicals Jan-Mar Earnings

• 10:36 PM ET Apr 08, 2025
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (29 total)

• 08:19 PM ET Apr 08, 2025
  

  EU considering banning use of carbon fibre in automobiles - Nikkei (pre-Japan open)

• 04:07 AM ET Mar 31, 2025
  

  Teijin to transfer all stake in Teijin Automotive Technologies to AURELIUS; terms undisclosed (¥1310.5000, 0)

• 12:40 AM ET Feb 25, 2025
  

  Teijin subsidiary J-TEC enters agreement with Metcela for manufacturing JRM-001 for treatment of single ventricle disease (¥1298.0000, -6)

• 09:39 PM ET Feb 05, 2025
  

  Teijin reports Q3 net income attributable ¥104.3B vs year-ago ¥12.7B (¥1282.0000, +11.5)